studies have indicated that: with imipramine, there is a high
rate of relapse with the discontinuation of imipramine, somewhere between
56 and 76%; with no treatment, an estimated 85% of children per
year will continue to have nocturnal enuresis without intervention;
and with hypnotherapy, the rate of relapse following the teaching
of hypnotherapy ranged between 16 and 32%.
In this study, at the 9 month f/u, hypnotherapy was significantly more
effective than imipramine (p<0.01). For various reasons, however,
the study was not very valid. With some adjustments, estimates
could be made which include the following:
Although only one study could be found comparing these 2 treatments,
and although the validity of the study is poor, the risks of treatment
are low, suggesting that it may be worth a trial.
Because of the benign nature of hypnotherapy in the form of Dry All
Night, (no known side effects compared to imipramine, no safety
issues for other children in the family, little effort on the part of
the parents, low cost, and the nature of the therapy allowing the child
to take control of and pride in the therapeutic process), this therapy
is a reasonable first line treatment.
Between 1.6 and 2.8 patients (NNT = 2-3) would need to be treated
with hypnotherapy instead of imipramine to relieve sleepwetting in
one child 9 months later.
Hypnotherapy reduced the risk (RRR) of continued sleepwetting 9 months
later by 43 to 73% over imipramine.